Literature DB >> 8175974

Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man.

G La Villa1, C Fronzaroli, C Lazzeri, C Porciani, R Bandinelli, S Vena, G Messeri, F Franchi.   

Abstract

We evaluated the effects of pathophysiological levels of human brain natriuretic peptide (BNP), a recently identified cardiac hormone with natriuretic activity, by determining the hemodynamic and renal responses to low dose infusion (4 pmol/kg.min for 1 h, from 1500-1600 h) of human synthetic BNP in five healthy volunteers in a randomized placebo-controlled crossover study. Compared to placebo, BNP induced significant increases in effective renal plasma flow (para-aminohippurate clearance), glomerular filtration rate (creatinine clearance), urine flow rate, and sodium excretion without affecting blood pressure, heart rate, cardiac output (echocardiographic method), peripheral vascular resistance, PRA, plasma aldosterone, or plasma norepinephrine to any significant extent. Exploration of segmental sodium handling by the lithium clearance technique showed that the natriuretic effect of BNP was due to both an increase in filtered sodium load and a reduced distal sodium reabsorption. These results indicate that the high plasma BNP levels observed in disease states, such as heart failure, may contribute to the regulation of renal hemodynamics and sodium excretion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8175974     DOI: 10.1210/jcem.78.5.8175974

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart failure.

Authors:  Clyde W Yancy
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 2.  Nesiritide: a review of its use in acute decompensated heart failure.

Authors:  Gillian M Keating; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Rationale and design of a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of B-type natriuretic peptide for the preservation of left ventricular function after anterior myocardial infarction.

Authors:  S Jeson Sangaralingham; John C Burnett; Paul M McKie; John A Schirger; Horng H Chen
Journal:  J Card Fail       Date:  2013-08       Impact factor: 5.712

4.  Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure.

Authors:  Tom D J Smilde; Kevin Damman; Pim van der Harst; Gerjan Navis; B Daan Westenbrink; Adriaan A Voors; Frans Boomsma; Dirk J van Veldhuisen; Hans L Hillege
Journal:  Clin Res Cardiol       Date:  2008-10-31       Impact factor: 5.460

5.  A retrospective characterization of worsening renal function in patients with acute decompensated heart failure receiving nesiritide.

Authors:  Jessica A Starr; Jean M Nappi
Journal:  Pharm Pract (Granada)       Date:  2009-03-15

6.  Higher serum concentrations of N-terminal pro-B-type natriuretic peptide associate with prevalent hypertension whereas lower associate with incident hypertension.

Authors:  Ekim Seven; Lise L N Husemoen; Hans Ibsen; Nele Friedrich; Matthias Nauck; Kristian Wachtell; Allan Linneberg; Jørgen L Jeppesen
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

7.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

Review 8.  Current strategies for preventing renal dysfunction in patients with heart failure: a heart failure stage approach.

Authors:  Victor Sarli Issa; Lúcia Andrade; Edimar Alcides Bocchi
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.